Galen in pact with US rival to end patent wrangles

Galen, the women's healthcare group, has tied up a wide-ranging and innovative deal with its US rival, Barr Laboratories, that ends most patent litigation between the pair and fends off copycat competition to several of its important drugs.

Galen shares jumped 8 per cent to 657.5p on the news, which analysts said removed a number of the competition fears that have dogged the stock this year.

Barr, which attempted to buy Galen earlier this year, is paying $45m (£28m) to acquire one off-patent contraceptive and the right to sell generic versions of two hormone replacement therapies shortly before their patents expire later this decade.

The deal settles patent litigation between the two companies over the HRT treatments Estrostep and femhrt, protecting Galen's exclusivity - and, hence, its high margins - over the products until 2007 and 2009 respectively.

There is also an innovative deal on Ovcon, Galen's most important contraceptive pill. Barr has lined up a cut-price copy of the drug, but Galen has bought an option to sell it on Barr's behalf. This would ensure the price is not eroded at least until Galen is able to launch an improved, patent-protected version of the drug.

Both companies have received advice from their lawyers that the deal will not fall foul of competition authorities in the US, who have previously shown themselves ready to use anti-trust laws to hasten the switch from branded drugs to cheaper copies.

Loestrin, the contraceptive pill that is being sold to Barr, was not being actively marketed by Galen, according to the chairman, John King. Loestrin, which was acquired from Pfizer this year, already faces generic competition and had sales of $16.7m (£10.5m) in the last three months.

Dr King said: "This deal has removed three of the risk factors that have been hanging over us. We have always taken a robust attitude to patent rights and we are confident in our ability to defend other patents."

There is still one outstanding issue between Barr and Galen, over the patents for Sarafem, a treatment for severe menstrual tension which Galen bought last year and whose patents are being challenged by Barr. The two are scheduled to clash in a US court in November.

Galen has repeatedly been criticised for providing only limited information on the existence and progress of its patent disputes.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Content Writer - Global Financial Services

£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...

Recruitment Genius: Web Developer - PHP

£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...

Recruitment Genius: Field Sales Consultant - Financial Services - OTE £65,000

£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Loan Underwriter

£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...

Day In a Page

Orthorexia nervosa: How becoming obsessed with healthy eating can lead to malnutrition

Orthorexia nervosa

How becoming obsessed with healthy eating can lead to malnutrition
Lady Chatterley is not obscene, says TV director

Lady Chatterley’s Lover

Director Jed Mercurio on why DH Lawrence's novel 'is not an obscene story'
Farmers in tropical forests are training ants to kill off bigger pests

Set a pest to catch a pest

Farmers in tropical forests are training ants to kill off bigger pests
Mexico: A culture that celebrates darkness as an essential part of life

The dark side of Mexico

A culture that celebrates darkness as an essential part of life
Being sexually assaulted was not your fault, Chrissie Hynde. Don't tell other victims it was theirs

Being sexually assaulted was not your fault, Chrissie Hynde

Please don't tell other victims it was theirs
A nap a day could save your life - and here's why

A nap a day could save your life

A midday nap is 'associated with reduced blood pressure'
If men are so obsessed by sex, why do they clam up when confronted with the grisly realities?

If men are so obsessed by sex...

...why do they clam up when confronted with the grisly realities?
The comedy titans of Avalon on their attempt to save BBC3

Jon Thoday and Richard Allen-Turner

The comedy titans of Avalon on their attempt to save BBC3
The bathing machine is back... but with a difference

Rolling in the deep

The bathing machine is back but with a difference
Part-privatised tests, new age limits, driverless cars: Tories plot motoring revolution

Conservatives plot a motoring revolution

Draft report reveals biggest reform to regulations since driving test introduced in 1935
The Silk Roads that trace civilisation: Long before the West rose to power, Asian pathways were connecting peoples and places

The Silk Roads that trace civilisation

Long before the West rose to power, Asian pathways were connecting peoples and places
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal are ennobled

The honours that shame Britain

Outcry as donors, fixers and MPs caught up in expenses scandal are ennobled
When it comes to street harassment, we need to talk about race

'When it comes to street harassment, we need to talk about race'

Why are black men living the stereotypes and why are we letting them get away with it?
International Tap Festival: Forget Fred Astaire and Ginger Rogers - this dancing is improvised, spontaneous and rhythmic

International Tap Festival comes to the UK

Forget Fred Astaire and Ginger Rogers - this dancing is improvised, spontaneous and rhythmic
War with Isis: Is Turkey's buffer zone in Syria a matter of self-defence – or just anti-Kurd?

Turkey's buffer zone in Syria: self-defence – or just anti-Kurd?

Ankara accused of exacerbating racial division by allowing Turkmen minority to cross the border